Riskpilot← Back to searchSign inGet full accessMedilang Oy
OYDissolvedY-tunnus 2650075-9Asematie 13-B44Medical specialists activities · NACE 8622Est. 2014— employees
Revenue 2025
EUR 327K
+12% vs 2024
EBITDA margin
77.2%
-37% vs 2024
Equity ratio
90.2%
Financial strength
Net profit 2025
EUR 198K
+14% vs 2024
| Revenue | EUR 327K | +12% |
| EBITDA | EUR 252K | -37% |
| Net profit | EUR 198K | +14% |
| Total assets | EUR 944K | +17% |
| Equity | EUR 852K | +20% |
| Employees | — | — |
Legal name
Medilang Oy
Y-tunnus number
2650075-9
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
24. lokakuuta 2014
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-11-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Lääkäripalvelujen tuottaminen potilaille, alan koulutus- ja konsultointi sekä kustannustoiminta. Erilaisten terveydenhoitovälineiden ja -tarvikkeiden maahantuonti, tukku- ja vähittäiskauppa. Yhtiö voi omistaa, hallita ja vuokrata sekä välittää kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa.
Address
Asematie 13-B44
Phone
+3580451109281
Email
jana.lang@fimnet.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 52 | 144 | 0 | 292 | 327 |
| Staff expenses | −4 | −0 | −0 | 0 | −0 |
| EBITDA | 16 | 99 | 0 | 401 | 252 |
| Depreciation & amort. | −0 | −0 | −0 | 1 | −1 |
| EBIT | 16 | 99 | 0 | 222 | 252 |
| Net financials | — | 0 | 0 | — | — |
| Profit before tax | 16 | 99 | 0 | 217 | 248 |
| Tax | 3 | 20 | −0 | 43 | −50 |
| Net profit | 13 | 79 | 0 | 173 | 198 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 461 | 515 | 701 | 808 | 944 |
| Equity | 460 | 503 | 584 | 710 | 852 |
| Long-term debt | — | — | 83 | 69 | 56 |
| Short-term debt | 1 | 12 | 34 | 29 | 37 |
| Total debt | 1 | 12 | 117 | 98 | 92 |
EBITDA margin
77.2%
This company
15.8%
Market median
+389% vs market
20212025
Equity ratio
90.2%
This company
38.2%
Market median
+136% vs market
20212025
Return on equity
23.3%
This company
18.4%
Market median
+27% vs market
20212025
Net profit margin
60.6%
This company
8.1%
Market median
+648% vs market
20212025
Asset turnover
0.35×
This company
1.12×
Market median
-69% vs market
20212025
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-12-01 – 2025-11-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-12-01 – 2021-11-30
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
JL Chief Executive Officer | Chief Executive Officer | 2014 |
JM Deputy Member | Deputy Member | 2014 |
JA | Audit | 2025 |
PR Deputy auditor | Deputy auditor | 2025 |
| Former (1) | ||
NP | Audit | 2016 – 2023 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medilang Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jaana Lang-Hurme | Chief Executive Officer | 0 companies |
| Jaana Marita Suni | Deputy Member | 0 companies |
| Jose Adam Juhani Kautonen | Audit | 0 companies |
| Niina Pauliina Lettojärvi | Audit | 0 companies |
| Petteri Raine Lagus | Deputy auditor | 0 companies |